Danta M, Barber D A, Zhang H P, Lee-Ng M, Baumgart S W L, Tsai V W W, Husaini Y, Saxena M, Marquis C P, Errington W, Kerr S, Breit S N, Brown D A
St Vincent's Clinical School, Faculty of Medicine, UNSW, Sydney, NSW, Australia.
Department of Gastroenterology, St Vincent's Hospital, Sydney, NSW, Australia.
Aliment Pharmacol Ther. 2017 Aug;46(3):347-354. doi: 10.1111/apt.14156. Epub 2017 Jun 1.
Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15) concentration has been associated with colonic adenomas and carcinoma.
To determine whether circulating MIC-1/GDF15 serum concentrations are higher in the presence of adenomas and whether the level decreases after excision.
Patients were recruited prospectively from a single centre and stratified into five groups: no polyps (NP); hyperplastic polyps (HP); sessile serrated ademona (SSA); adenomas (AP); and colorectal carcinoma (CRC). Blood samples were collected immediately before and 4 weeks after colonoscopy. MIC-1/GDF15 serum levels were quantified using ELISA.
Participants (n=301) were stratified as: NP; n=116 (52%), HP; n=37 (12%), SSA; n=19 (7%), AP; n=68 (23%); and CRC; n=3 (1%). Patients were excluded from the study due to nondiagnostic pathology (n=9, 3%) and exclusion criteria (n=20, 6%). In the 272 remaining subjects (M=149; F=123), age (P=.005), history of colonic polyps (P=.003) and family history of colonic polyps (P=.002) were associated with presence of adenomas. Baseline median MIC-1/GDF15 serum levels increased significantly from NP 609 (460-797) pg/mL, HP 582 (466-852) pg/mL, SSA 561 (446-837) pg/mL to AP 723 (602-1122) pg/mL and CRC 1107 (897-1107) pg/mL; (P<.001). In the pre- and postpolypectomy paired adenoma samples median MIC-1/GDF15 reduced significantly from 722 (603-1164) pg/mL to 685 (561-944) pg/mL (P=.002). A ROC analysis for serum MIC-1/GDF15 to identify adenomatous polyps indicated an area under the curve of 0.71.
Our data suggest that serum MIC-1/GDF15 has the diagnostic characteristics to increase the detection of colonic neoplasia and improve screening.
血清巨噬细胞抑制细胞因子-1(MIC-1/GDF15)浓度与结肠腺瘤和癌有关。
确定存在腺瘤时循环MIC-1/GDF15血清浓度是否更高,以及切除后该水平是否降低。
前瞻性地从单一中心招募患者,并分为五组:无息肉(NP);增生性息肉(HP);无蒂锯齿状腺瘤(SSA);腺瘤(AP);以及结直肠癌(CRC)。在结肠镜检查前和检查后4周立即采集血样。使用酶联免疫吸附测定法对MIC-1/GDF15血清水平进行定量。
参与者(n = 301)分层如下:NP,n = 116(52%);HP,n = 37(12%);SSA,n = 19(7%);AP,n = 68(23%);以及CRC,n = 3(1%)。因病理诊断不明确(n = 9,3%)和排除标准(n = 20,6%),患者被排除在研究之外。在其余272名受试者(男性 = 149;女性 = 123)中,年龄(P = 0.005)、结肠息肉病史(P = 0.003)和结肠息肉家族史(P = 0.002)与腺瘤的存在相关。基线时MIC-1/GDF15血清水平中位数从NP组的609(460 - 797)pg/mL、HP组的582(466 - 852)pg/mL、SSA组的561(446 - 837)pg/mL显著升高至AP组的723(602 - 1122)pg/mL和CRC组的1107(897 - 1107)pg/mL;(P < 0.001)。在息肉切除术前和术后配对的腺瘤样本中,MIC-1/GDF15中位数从722(603 - 1164)pg/mL显著降至685(561 - 944)pg/mL(P = 0.002)。血清MIC-1/GDF15用于识别腺瘤性息肉的ROC分析表明曲线下面积为0.71。
我们的数据表明,血清MIC-1/GDF15具有增加结肠肿瘤检测和改善筛查的诊断特征。